Physician profile
Katie Hebert
NPI 1942765326
$8,563.03
in general payments reported to CMS, 2019-2025
32 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,009 · 2022: $1,170 · 2023: $1,801 · 2024: $2,030 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,290 · Education: $94.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,289.56 |
| Education | $94.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,918.44 | 2021-2025 | |
| Gilead Sciences, INC. | $946.14 | 2021-2025 | Epclusa |
| Madrigal Pharmaceuticals | $745.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $669.96 | 2021-2025 | Entyvio, Eohilia |
| Redhill Biopharma INC. | $482.72 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Phathom Pharmaceuticals, INC. | $428.52 | 2024-2025 | Voquezna |
| Celgene Corporation | $417.32 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $378.87 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.75 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $256.53 | 2021-2025 | |
| Ardelyx, INC. | $251.05 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $184.07 | 2021-2024 | Linzess |
| Dexcom, INC. | $165.44 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Medtronic, INC. | $145.62 | 2024 | Interstim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.77 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $136.75 | 2024-2025 | |
| Novo Nordisk INC | $135.47 | 2024-2025 | Wegovy |
| Qol Medical, LLC | $113.07 | 2021-2025 | Sucraid |
| Inspire Medical Systems, INC. | $111.43 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $103.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $96.98 | 2024 | |
| Ferring Pharmaceuticals INC. | $75.58 | 2022-2023 | Rebyota |
| Axonics, INC. | $73.73 | 2024 | Axonics |
| Intercept Pharmaceuticals, INC. | $68.48 | 2021-2025 | |
| Braintree Laboratories, INC. | $46.32 | 2021-2023 | Suflave |
| Lilly USA, LLC | $40.28 | 2023-2024 | Omvoh |
| Merck Sharp & Dohme LLC | $30.82 | 2024 | Dificid |
| Ironshore Pharmaceuticals INC. | $17.32 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2023 | |
| Evoke Pharma, INC. | $12.80 | 2023 | Gimoti |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.